Motavizumab: Humanized anti-RSV monoclonal antibody prevention of RSV infection

Drugs of the Future

Volumn 33, Issue 3, 2008, Pages 203-205

  Madaan, Arvind ^a  

^a Danville ENT Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOTAVIZUMAB; PALIVIZUMAB; PLACEBO;

CLINICAL TRIAL; DRUG BINDING; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; NONHUMAN; PNEUMONIA; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; SHORT SURVEY; SKIN ALLERGY; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT; VIRAL BRONCHIOLITIS; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

EID: 42449090206     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.03.1185672     Document Type: Short Survey

References (15)

1. Peebles, R.S. Jr., Sheller, J.R., Collins, R.D. et al. Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. J Med Virol 2001, 63(2): 178-88.
2. Shay, D.K., Holman, R.C., Newman, R.D. et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA - J Am Med Assoc 1999, 282(15): 1440-6.
3. Collins, P.L., Murphy, B.R. New generation live vaccines against human RSV designed by reverse genetics. Proc Am Thorac Soc 2005, 2(2): 166-73.
4. Numax® achieves primary endpoint among high-risk infants versus current standard of care and shows reduction of medically attended outpatient RSV-related lower respiratory infections. MedImmune, Inc. Press Release, May 8, 2007.
5. Harris, J., Werling, D. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol 2003, 5(10): 671-80.
6. Openshaw, P.J., Tregoning, J.S. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005, 18(3): 541-55.
7. Mejias, A., Chávez-Bueno, S., Ríos, A.M. et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 2004, 48(5): 1811-22.
8. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003, 112(6, Pt. 1): 1442-6.
9. Wu, H., Pfarr, D.S., Losonsky, G.A., Kiener, P.A. Immunoprophylaxis of RSV infection: Advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008, 317: 103-23.
10. Wu, H., Pfarr, D.S., Johnson, S. et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007, 368(3): 652-65.
11. Mejias, A., Chavez-Bueno, S., Rios, A.M. et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: Time versus potency. Antimicrob Agents Chemother 2005, 49(11): 4700-7.
12. Mejias, A., Chavez-Bueno, S., Raynor, M.B. et al. Motavizumab, a neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by RSV in the mouse model. Virol J 2007, 4: 109.
13. Wu, H., Pfarr, D.S., Tang, Y. et al. Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005, 350(1): 126-44.
14. Motavizumab reduced RSV hospitalizations by 83 percent among high-risk Native American, full-term infants in placebo-controlled phase 3 study. MedImmune, Inc. Press Release, August 23, 2007.
15. MedImmune submits Biologics License Application to FDA for motavizumab. Medlmmune, Inc. Press Release, February 4, 2008.